Strike Pharma develops a pipeline of in vivo CAR therapies for autoimmune disease and cancer based on a proprietary technology for targeted LNP delivery. The lead asset is a first-in-class in vivo CAR-M depleting tissue infiltrating T cells for the treatment of T cell-dependent inflammatory disease.
Learn more about our science here: